Join the 'Victoza' group to help and get support from people like you.

Victoza Blog

Diabetes Drug May Spur Weight Loss in Obese Nondiabetics

Posted 30 May 2014 by Drugs.com

THURSDAY, May 29, 2014 – The diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. In this test of its effectiveness as a diet aid, people taking Victoza for over a year lost an average of 8 percent of their body weight, compared with 2.6 percent shed by those taking a placebo (dummy drug), researchers found. "Liraglutide, an injection treatment already approved for diabetes treatment, can help reduce body weight in people with obesity when used at a higher dose than is usually used in diabetes," said lead researcher Dr. John Wilding, head of the department of obesity and endocrinology at the University of Liverpool in England. "These results suggest liraglutide is effective and overall well-tolerated for obesity treatment," he said. Although this study didn't compare Victoza with other weight loss drugs, Wilding said that a ... Read more

Related support groups: Obesity, Victoza, Liraglutide

Study Sees No Evidence Linking Diabetes Drugs With Pancreatic Cancer

Posted 26 Feb 2014 by Drugs.com

WEDNESDAY, Feb. 26, 2014 – There's no firm evidence that the type 2 diabetes medications known as incretin-based drugs cause pancreatitis or pancreatic cancer, U.S. and European health officials say. But it's too early to say there's definitely no link between the injectable drugs and pancreatitis or pancreatic cancer, according to the safety assessment by the U.S. Food and Drug Administration (FDA) and its counterpart overseas, the European Medicines Agency (EMA). "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data," states the report in the Feb. 27 issue of the New England Journal of Medicine. "The FDA and the EMA have not reached a final conclusion at this time regarding such a causal ... Read more

Related support groups: Victoza, Januvia, Pancreatitis, Byetta, Bydureon, Pancreatic Cancer, Onglyza, Sitagliptin, Exenatide, Liraglutide, Saxagliptin

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

Posted 14 Mar 2013 by Drugs.com

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics. BACKGROUND: Drugs in the incretin mimetic class include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Byetta, Janumet, Bydureon, Tradjenta, Sitagliptin, Exenatide, Liraglutide, Jentadueto, Linagliptin, Nesina, Alogliptin/pioglitazone, Kazano, Oseni, Alogliptin, Alogliptin/metformin, Simvastatin/sitagliptin, Linagliptin/metformin

Certain Diabetes Medications May Lower Heart Failure Risk

Posted 10 Mar 2013 by Drugs.com

SUNDAY, March 10 – A newer class of diabetes drugs may offer an extra benefit: A new study suggests these medications lower the odds of suffering heart failure. Researchers from Henry Ford Hospital in Detroit found that patients taking so-called GLP-1 drugs – including brand-name medications such as Byetta, Januvia and Victoza – were more than 40 percent less likely to be hospitalized for heart failure than patients prescribed other blood sugar-lowering medications. GLP-1 diabetes drugs have been in use for only the last several years and are considered second-line treatments after well-established medications such as metformin, physicians said. "I don't think we can say this will magically prevent all heart failure deaths, but the strength of the association warrants more investigation," said study author and cardiologist Dr. David Lanfear. "Heart failure is a very common disease . ... Read more

Related support groups: Diabetes, Type 2, Victoza, Heart Failure, Congestive Heart Failure, Januvia, Byetta, Bydureon, Sitagliptin, Exenatide, Liraglutide

New Diabetes Drugs Have Different Advantages, Study Says

Posted 7 Nov 2012 by Drugs.com

WEDNESDAY, Nov. 7 – A head-to-head comparison of two new type 2 diabetes drugs produced mixed results. In the study, liraglutide (Victoza) was somewhat better than the other drug, exenatide (Bydureon), in lowering blood sugar and weight, but Bydureon was associated with fewer side effects, researchers said. Victoza is injected daily by patients and Bydureon is injected weekly. Both drugs are classified as "glucagon-like peptide-1 receptor agonists." "These treatments are very powerful blood sugar-lowering agents that don't cause [too-low] blood sugar and are associated with weight loss," said lead researcher Dr. John Buse, a professor of medicine at the University of North Carolina at Chapel Hill. "That's a unique profile for a diabetes drug." Patients can choose between them, Buse said. A lot depends on what the person is comfortable with. "You lay this all out for patients and help ... Read more

Related support groups: Diabetes, Type 2, Victoza, Byetta, Bydureon, Exenatide, Liraglutide

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

Posted 9 Apr 2012 by Drugs.com

Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin] injection) to include data showing superior blood sugar control when compared to Januvia (sitagliptin). Victoza also provided greater weight reduction. Both products were taken in combination with metformin in adults with type 2 diabetes. The update also includes data demonstrating the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes. “We’re pleased to expand the Victoza product label to include data demonstrating superior efficacy over Januvia, said Camille Lee, Corporate Vice President, Diabetes Marketing at Novo Nordisk. “The additional data supporting combination therapy with basal insulin further demonstrates that Victoza is ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Sitagliptin, Liraglutide

FDA Medwatch Alert: Victoza (liraglutide [rDNA origin]) Injection: REMS - Risk of Thyroid C-cell Tumors, Acute Pancreatitis

Posted 13 Jun 2011 by Drugs.com

ISSUE: Novo Nordisk reminded healthcare professionals of important safety information about Victoza (liraglutide [rDNA origin]) injection required in a Risk Evaluation and Mitigation Strategy (REMS). The letter is being sent because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza. Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. Additionally, in clinical trials studying Victoza, there were more cases of pancreatitis in patients treated with Victoza than in patients treated with ... Read more

Related support groups: Victoza

Ask a Question

Further Information

Related Condition Support Groups

Obesity, Diabetes, Type 2, Diabetes, Type 1

Victoza Patient Information at Drugs.com